AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE Randomized, Controlled Trial
AgNovos Bioscience, a medical technology company working to transform the treatment of bone disease by addressing persistent unmet needs in the care of patients, announced today that it has enrolled the 150th patient in the clinical study titled “Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures” (RESTORE). RESTORE is a randomized, controlled, prospective, single-blinded, global study designed to evaluate whether women undergoing surgical repair of a fragility hip fracture, and treated contralaterally with the AGN1 LOEP kit, are at reduced risk of a second hip fracture. The Company has activated more than 30 study sites across Japan, Germany, Spain, France, Italy, the UK, the Netherlands and Austria. RESTORE is expected to include more than 50 study sites and enroll at least 650 patients.
“The initiation of RESTORE and the enrollment of the 150th patient is a major milestone for the Company,” explained James Pilachowski, Senior Vice President of Hip Program. “RESTORE will be one of the largest prospective orthopaedic trauma studies ever conducted. The data generated will be critical to our efforts to gain access to new markets, including the U.S. and Japan.”
To ensure strategic study oversight and guidance, AgNovos Bioscience, Inc. has chartered a global steering committee comprised of experts in orthopaedics, trauma, metabolic bone health, internal medicine and medical ethics. The committee is co-chaired by Dr. Serge Ferrari, head of the Clinical Service and Research Laboratory of Bone Diseases at the Geneva University Hospital (Switzerland) and Dr. Paul Tornetta, director of the Orthopaedic Trauma department at Boston Medical Center (USA).
Dr. Tornetta shared his perspective on the importance of the study: “We all know that fragility hip fractures will be one of the biggest challenges facing orthopaedic surgeons over the next 10-20 years. Addressing contralateral hip fracture risk will be key to meeting that challenge. The science and research supporting this treatment is positive. I am glad the study is underway; I think that it could make a real difference.”
Dr. Ferrari noted that “pharmacological approaches to treatment of osteoporosis are very important but are not sufficient by themselves to solve the challenge of secondary fracture risk, especially in patients with recent fractures. The incremental risk of fracture for these patients is highest during the first year following the index fracture. If this study is successful, orthopaedic surgeons will have an important new role to play in our efforts to reduce secondary hip fracture risk.”
More than two million hip fragility fractures occur globally every year. Hip fragility fractures result from low-energy trauma such as a fall from standing height or less. These fractures are associated with significant morbidity and mortality, and often create significant burden for affected individuals, families and healthcare systems. Although multiple factors contribute to hip fracture risk, a key factor is osteoporosis and related bone loss and fragility.
“One of the reasons hip fragility fractures are so devastating is that individuals suffering one fracture are at increased risk for a second,” explained Dr. James Howe, the Co-Founder and Chief Medical Officer of AgNovos Bioscience, Inc. “The outcomes of second fractures are often even worse than those of the first. I saw this pattern during my decades of clinical practice in orthopaedics. I look forward to reviewing the data generated by RESTORE with other clinicians and organizations committed to addressing secondary hip fracture risk.”
About the AGN1 LOEP Kit
The AGN1 LOEP Kit contains the instruments and materials to perform a minimally invasive procedure to implant AGN1, a proprietary, calcium-based, osteoconductive, and tri-phasic implant material. AGN1 is uniquely formulated with a cell-friendly surface architecture and a resorption profile that enables the rapid formation of new bone. Clinical research has shown that AGN1 LOEP treatment delivers rapid, substantial and durable increase in the strength of osteoporotic femurs. The kit is available in Europe under the brand name OSSURE™ LOEP kit.
About AgNovos Bioscience, Inc.
AgNovos Bioscience, Inc. is a medical technology company developing new therapies that leverage proprietary, bone-building technology and regenerative medicine to address unmet needs in the treatment of bone disease. AgNovos Bioscience, Inc. is privately held and has its corporate headquarters in New York City with manufacturing, research & development, and corporate support services located in Rockville, MD. www.agnovos.com
CAUTION The OSSURE (LOEP) kit is not cleared for use in the United States.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Associate Vice President, Spine Program and Marketing
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Settlement Administrator Angeion Group Announces Proposed Settlement In U.S. Dollar LIBOR-Based Instrument Class Action22.9.2023 16:00:00 EEST | Press release
There are lawsuits impacting individuals and institutions that entered into over-the-counter financial derivative and non-derivative instruments directly with 17 banks and that received payments tied to U.S. Dollar LIBOR. A Settlement totaling $101 million has been reached with Coöperatieve Rabobank U.A. (“Rabobank”), Lloyds Banking Group plc, Lloyds Bank plc, HBOS plc, and Bank of Scotland plc (together, “Lloyds”), Royal Bank of Canada (“RBC”), and Portigon AG and Westdeutsche Immobilien Servicing AG (together “Portigon”). Earlier settlements totaling $680 million were reached with Barclays, Citibank, Deutsche Bank, HSBC, MUFG, Norinchukin, and SocGen bringing the total settlement amount to $781 million. The remaining Non-Settling Defendants include Bank of America, Credit Suisse, JPMorgan Chase, Royal Bank of Scotland, and UBS. What does the Settlement provide? The Settlement will create a Settlement Fund totaling $101 million that will be used to pay eligible Class Members who submi
Kenvue to Announce Third Quarter 2023 Results on October 26, 202322.9.2023 13:30:00 EEST | Press release
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the third quarter ending October 1, 2023, before market open on October 26, 2023. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its third quarter results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or 201-689-8779 from international locations. A live webcast of the conference call will be available at https://investors.kenvue.com. A replay will be available approximately two hours after the live event. About Kenvue Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary
OS Achieves 800-Puff Milestone with FEELM Max Technology22.9.2023 12:34:00 EEST | Press release
A significant mark in the vaping industry was set when OS Vape, a pioneering disposable product series from OS, showcased its dynamic range at the InterTabac from September 14th to 16th in Germany. Recognized as a leading brand in Germany's shisha product market, OS boasts an extensive local network of channels. Drawing upon this rich resource base, OS's foray into the disposable e-cigarette domain promises consumers enhanced puff counts, cost-efficiency, and unparalleled vapor consistency. As revealed by Future Marketing Insights, Europe's disposable market witnessed a substantial surge, accounting for a 32.3% revenue share in 2022. This robust growth underscores the escalating consumer preference for hassle-free, smokeless alternatives that eliminate the need for recharges or refills. The evolution of the disposable sector brings heightened convenience and a broader array of choices for consumers. Capitalizing on this trend, OS, through its innovative product series and leveraging it
Earnix Announces New London Office, Unveils New Tech and Launches Global Modelling Contest at Earnix Eˣcelerate Summit 202322.9.2023 11:00:00 EEST | Press release
Earnix, the global provider of intelligent, SaaS solutions for insurers and banks, celebrated its 12th annual Eˣcelerate Summit by announcing a new London office to collaborate with its growing customer base, unveiling Model Accelerator, and launching its first global modelling contest. Held September 20-21 in London, Earnix Eˣcelerate brought together hundreds of financial services business leaders to discuss insurance insights, perspectives, case studies and approaches impacting the evolution of the industry. “Earnix Eˣcelerate was a world-class event dedicated to discussing industry challenges and discovering the latest technology innovation to address them,” said Karun Arathil, senior analyst, Celent. “I found the forum engaging and interactive, and it was great to exchange ideas and gain perspective with industry leaders from around the world.” In other news, Earnix announced a new upgraded office presence in London, located in Devonshire Square. The space affords local employees
Europe’s Enterprises Look to Providers to Bridge the CX Gap22.9.2023 11:00:00 EEST | Press release
Enterprises throughout Europe are rapidly moving from in-house operations to external service providers to meet the growing demand for an enhanced contact center customer experience (CX), according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2023 ISG Provider Lens™ Customer Experience Services report for Europe finds that most executives in Europe and worldwide consider CX a top strategic priority and intend to “completely protect” CX from cost optimization programs. Providers are responding to this increased demand by delivering advanced, location-independent CX with high AI and automation content, the report says. “Over the past few years, the need for resilient and advanced digital CX has increased dramatically,” said Jill Stabler, partner, ISG Enterprise. “This has led to a corresponding surge of activities in this space.” Technology has played a crucial role in shaping the C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom